335 related articles for article (PubMed ID: 19877243)
1. When does Parkinson's disease begin?
Gaig C; Tolosa E
Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
[TBL] [Abstract][Full Text] [Related]
2. Can we image premotor Parkinson disease?
Marek K; Jennings D
Neurology; 2009 Feb; 72(7 Suppl):S21-6. PubMed ID: 19221310
[TBL] [Abstract][Full Text] [Related]
3. Non-motor extranigral signs and symptoms in Parkinson's disease.
Wolters ECh
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
[TBL] [Abstract][Full Text] [Related]
4. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
5. [Non-motor disorders in Parkinson's disease].
Merello M
Rev Neurol; 2008 Sep 1-15; 47(5):261-70. PubMed ID: 18780273
[TBL] [Abstract][Full Text] [Related]
6. When does Parkinson's disease begin? From prodromal disease to motor signs.
Meissner WG
Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
[TBL] [Abstract][Full Text] [Related]
7. A timeline for Parkinson's disease.
Hawkes CH; Del Tredici K; Braak H
Parkinsonism Relat Disord; 2010 Feb; 16(2):79-84. PubMed ID: 19846332
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
Marek K; Jennings D; Tamagnan G; Seibyl J
Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
10. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
Banati RB; Daniel SE; Blunt SB
Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease: clinical aspects.
Klockgether T
Cell Tissue Res; 2004 Oct; 318(1):115-20. PubMed ID: 15365814
[TBL] [Abstract][Full Text] [Related]
12. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
13. Clinical criteria for the diagnosis of Parkinson's disease.
Reichmann H
Neurodegener Dis; 2010; 7(5):284-90. PubMed ID: 20616563
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of nigral cell death in Parkinson's disease.
Przedborski S
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
16. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
17. Clinical measures of progression in Parkinson's disease.
Poewe W
Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
Stern MB; Siderowf A
Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease risk score: moving to a premotor diagnosis.
Winkler J; Ehret R; Büttner T; Dillmann U; Fogel W; Sabolek M; Winkelmann J; Kassubek J
J Neurol; 2011 May; 258(Suppl 2):S311-5. PubMed ID: 21560061
[TBL] [Abstract][Full Text] [Related]
20. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
